-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The results of the centralized procurement of 45 varieties of the Guangdong 13-province alliance were announced, involving 313 product specifications and 130 pharmaceutical companies
.
The highest drop was 95%
.
Entecavir tablets (0.
5mg) of Beijing Biopharmaceuticals did not appear in the list of this selection
.
The rules of the alliance's centralized procurement are complicated, which may affect the next fourth and fifth batches of national procurement
.
At the same time, it will also have an impact on the continuation of national procurement in other provinces
.
On December 7, the Guangdong Pharmaceutical Trade Center announced the results of the batch procurement of 45 pharmaceutical groups including Amoxicillin in the Guangdong Union, involving 313 product regulations and 130 pharmaceutical companies
.
Compared with the previously selected varieties, the entecavir tablets (0.
5mg) of Beijing Baiao Pharmaceutical did not appear in the selected list (see the attached table at the end of the article for details)
.
Jilin Sichang Pharmaceutical's Moxifloxacin Hydrochloride and Sodium Chloride Injection (250ml: Moxifloxacin 0.
4g and Sodium Chloride 2.
0g), Hainan Prili Pharmaceutical's Levetiracetam Injection Concentrated Solution (5ml: 500mg), The three selected drugs of Levetiracetam Injection Concentrated Solution (5ml: 500mg) of Jichuan Pharmaceutical Group will be finalized and the selected prices will be determined after the medical institutions in the alliance area have completed the confirmation of the allocation
.
According to statistics, a total of 58 product regulations fell ≥50% this time.
The largest drop was escitalopram oxalate tablets from Zhejiang Jinhua Kangenbei, which fell by as much as 95% compared with the highest effective declaration price.
Sinopharm Group Langfang divided The company's dexmedetomidine hydrochloride injection, olanzapine tablets and escitalopram oxalate tablets of Guangdong Dongyang Sunshine were all reduced by no less than 80%, which were 89%, 85%, and 80%, respectively
.
In addition, the selected prices of 33 product regulations are less than 20 cents
.
Compared with the previously announced lowest prices for national belts, many manufacturers' quotations have largely floated, and some have even doubled
.
This means that under the rules of the Guangdong Union, the price of the original national selection of the lower selection has a chance to be increased.
Previously, the price increase of the second batch of renewed varieties of cefalexin in various provinces was an example.
.
This also shows that after the end of the original procurement cycle of National Procurement, the new price formation mechanism follows the rule that the market determines the price "increases and declines", and is under the background of the national centralized procurement principle (four stable and one stable).
, The original low-priced manufacturers are gradually getting out of the quagmire of low-cost supply
.
From the perspective of the selected price ladder, most companies won the bid at the P2 price, involving a total of 100 product specifications, and the other 64 product specifications P1 and P2 have the same price
.
According to the procurement rules, these companies selected by the P2 quotation meeting the relevant conditions are expected to get more shares of the reported volume
.
A list of valid quotation companies ≤ 2: P1 quotation corresponds to 60% of the company’s first year’s reported volume, P2 is more than 60% of the company’s reported volume; A list of valid quotation companies ≥ 3 and B list of companies that have reported volume: P1 is The company corresponds to 100% of the first year's reporting volume, and P2 exceeds 100% of the company
.
Companies that have reported volume alone: P1 corresponds to 100% of the company’s reporting volume in the first year, and P2 exceeds 100% of the company’s volume.
This time the Guangdong 13 Alliance’s centralized procurement rules are also unprecedented in complexity, which may affect the next fourth and fifth Approval of the continued work due to the national procurement
.
At the same time, it will also have an impact on the continuation of national procurement in other provinces
.
.
The highest drop was 95%
.
Entecavir tablets (0.
5mg) of Beijing Biopharmaceuticals did not appear in the list of this selection
.
The rules of the alliance's centralized procurement are complicated, which may affect the next fourth and fifth batches of national procurement
.
At the same time, it will also have an impact on the continuation of national procurement in other provinces
.
On December 7, the Guangdong Pharmaceutical Trade Center announced the results of the batch procurement of 45 pharmaceutical groups including Amoxicillin in the Guangdong Union, involving 313 product regulations and 130 pharmaceutical companies
.
Compared with the previously selected varieties, the entecavir tablets (0.
5mg) of Beijing Baiao Pharmaceutical did not appear in the selected list (see the attached table at the end of the article for details)
.
Jilin Sichang Pharmaceutical's Moxifloxacin Hydrochloride and Sodium Chloride Injection (250ml: Moxifloxacin 0.
4g and Sodium Chloride 2.
0g), Hainan Prili Pharmaceutical's Levetiracetam Injection Concentrated Solution (5ml: 500mg), The three selected drugs of Levetiracetam Injection Concentrated Solution (5ml: 500mg) of Jichuan Pharmaceutical Group will be finalized and the selected prices will be determined after the medical institutions in the alliance area have completed the confirmation of the allocation
.
According to statistics, a total of 58 product regulations fell ≥50% this time.
The largest drop was escitalopram oxalate tablets from Zhejiang Jinhua Kangenbei, which fell by as much as 95% compared with the highest effective declaration price.
Sinopharm Group Langfang divided The company's dexmedetomidine hydrochloride injection, olanzapine tablets and escitalopram oxalate tablets of Guangdong Dongyang Sunshine were all reduced by no less than 80%, which were 89%, 85%, and 80%, respectively
.
In addition, the selected prices of 33 product regulations are less than 20 cents
.
Compared with the previously announced lowest prices for national belts, many manufacturers' quotations have largely floated, and some have even doubled
.
This means that under the rules of the Guangdong Union, the price of the original national selection of the lower selection has a chance to be increased.
Previously, the price increase of the second batch of renewed varieties of cefalexin in various provinces was an example.
.
This also shows that after the end of the original procurement cycle of National Procurement, the new price formation mechanism follows the rule that the market determines the price "increases and declines", and is under the background of the national centralized procurement principle (four stable and one stable).
, The original low-priced manufacturers are gradually getting out of the quagmire of low-cost supply
.
From the perspective of the selected price ladder, most companies won the bid at the P2 price, involving a total of 100 product specifications, and the other 64 product specifications P1 and P2 have the same price
.
According to the procurement rules, these companies selected by the P2 quotation meeting the relevant conditions are expected to get more shares of the reported volume
.
A list of valid quotation companies ≤ 2: P1 quotation corresponds to 60% of the company’s first year’s reported volume, P2 is more than 60% of the company’s reported volume; A list of valid quotation companies ≥ 3 and B list of companies that have reported volume: P1 is The company corresponds to 100% of the first year's reporting volume, and P2 exceeds 100% of the company
.
Companies that have reported volume alone: P1 corresponds to 100% of the company’s reporting volume in the first year, and P2 exceeds 100% of the company’s volume.
This time the Guangdong 13 Alliance’s centralized procurement rules are also unprecedented in complexity, which may affect the next fourth and fifth Approval of the continued work due to the national procurement
.
At the same time, it will also have an impact on the continuation of national procurement in other provinces
.
